Post by Boehringer Ingelheim

#NEWS: People living with small cell lung cancer and other neuroendocrine carcinomas continue to face limited treatment options. Through a new clinical collaboration with Zai Lab, we are evaluating a dual DLL3‑targeting investigational combination, bringing together T-cell engagement and targeted drug delivery in a Phase Ib/II trial. By systematically broadening the profile of our cancer immunology compounds, we are advancing research that has the potential to transform the lives of people living with cancer, especially where current options fall short. Learn more: https://lnkd.in/dr24_Fbd #CancerResearch #ImmunoOncology #SmallCellLungCancer